[Progress in inflammation applicable to chronic evolutive polyarthritis].
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000941:Antigens / Q000032:analysis; D001168:Arthritis / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D002464:Cell Migration Inhibition; D000242:Cyclic AMP / Q000032:analysis; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology; D007111:Immunity, Cellular; D007249:Inflammation; D007962:Leukocytes / Q000276:immunology; D008213:Lymphocyte Activation; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000032:analysis; D013582:Synovial Fluid / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology; D013934:Thymectomy; D013950:Thymus Gland / Q000502:physiology; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D000941:Antigens; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D000242:Cyclic AMP
Progrès dans l'inflammation applicable à la polyarthrite chronique evolutive.